Annals of Internal Medicine reports that people who have a normal body mass index (weight to height ratio) but abdominal fat are at high risk for heart related deaths.
Using National Health and Nutrition Examination Survey data, researchers studied more than 15,000 adults with BMIs greater than 18.5. Normal being 18-24.
After a mean follow-up of 14 years, waist-to-hip ratio (WHR), but not BMI, was associated with higher overall mortality risk. Among men with normal BMI, those with central obesity had an 87% higher total mortality risk than men without central obesity. Similarly, women with normal-weight central obesity had a 48% higher mortality risk than women with similar BMI but no central obesity.
The recommended waist circumference for men is less than 102 cm, and for women is less than 88 cm.
An interesting article about young women and their habits– according to a study done by the Journal of the American College of Cardiology, young women with healthy habits are less likely to develop coronary heart disease or cardiovascular risk factors as they age,
They looked at six criteria in women aged 27-44 years of age
normal body mass index
physical activity of at least 2.5 hours weekly
television viewing of 7 hours or less weekly
moderate alcohol consumption
and a healthy diet —
These women had almost no heart disease and low rates of type 2 diabetes, hypertension, and high cholesterol after 20 years’ follow-up.
Compared with women who met none of the criteria, those meeting all six had a 92% reduction in risk for coronary heart disease and a 66% reduction in CV risk factors. Of note, only about 5% of study participants met all six criteria.
In a retrospective analysis, using metformin for >3 years reduced
stomach cancer risk by 43% in patients with type 2 diabetes who did
not use insulin.
However, the risk of stomach cancer risk was doubled in insulin users
versus nonusers, regardless of metformin use.
The oral antidiabetic drug metformin has demonstrated anticancer
activity in other studies as well.
Metformin slows prostate cancer growth in adjuvant setting (AACR,
103rd Annual Meeting2012),
boosts survival in ovarian cancer(Mayo Clinic,2012),
exhibits antineoplastic effect in patients with thyroid cancer
Kim Y-I et al. Long-term metformin use reduces gastric cancer risk in
type 2 diabetics without insulin treatment: A nationwide cohort study.
Aliment Pharmacol Ther 2014 Apr; 39:854. (http://dx.doi.org/10.1111/apt.12660
Angiotensin-converting–enzyme (ACE) inhibitors are associated with
reduced mortality and cardiovascular events in patients with diabetes,
while angiotensin-receptor blockers (ARBs) have little effect,
according to a meta-analysis in JAMA Internal Medicine.
Researchers assessed the results of 35 randomized, controlled studies
comprising some 56,000 patients. Participants had been randomized to
either the active group (ACE inhibitors or ARBs) or a comparator group
(placebo, no treatment, or other antihypertensive drugs).
Use of ACE inhibitors was associated with a 13% to 17% risk reduction
in all-cause mortality, cardiovascular mortality, and major
cardiovascular events. ARB users did not see a similar benefit.
However, ARBs were associated with a 30% risk reduction in heart
The authors conclude that ACE inhibitors “should be considered as
first-line therapy to limit the excess mortality and morbidity in this
JAMA Internal Medicine article